For the quarter ending 2025-09-30, KYMR made $2,764K in revenue. -$80,953K in net income. Net profit margin of -2928.84%.
| Income Statement | 2025-09-30 | 2025-06-30 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|
| Collaboration revenue | 2,764 | 11,476 | 14,444 | 3,741 |
| Research and development | 74,094 | 78,388 | 59,946 | 60,410 |
| General and administrative | 17,336 | 17,645 | 16,026 | 15,455 |
| Impairment of long-lived assets | 3,855 | 0 | 1,231 | - |
| Total operating expenses | 95,285 | 96,033 | 77,614 | 75,865 |
| Loss from operations | -92,521 | -84,557 | -63,170 | -72,124 |
| Interest and other income | 10,444 | 8,051 | 9,443 | 9,697 |
| Interest and other expense | 98 | 108 | 63 | 60 |
| Total other income | 10,346 | 7,943 | 9,380 | 9,637 |
| Net loss | -82,175 | -76,614 | -53,790 | -62,487 |
| Unrealized gain on marketable securities | 1,222 | 337 | -1,654 | 4,030 |
| Total comprehensive loss | -80,953 | -76,277 | -55,445 | -58,457 |
| Net loss per share, basic | -0.94 | -0.95 | -0.72 | -0.82 |
| Net loss per share, diluted | -0.94 | -0.95 | -0.72 | -0.82 |
| Weighted average common shares outstanding, basic | 87,300,286 | 80,449,405 | -360,661.333 | 76,125,975 |
| Weighted average common shares outstanding, diluted | 87,300,286 | 80,449,405 | -360,661.333 | 76,125,975 |
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)